Oxford Biomedica strikes new AAV agreements with US firms
Sharecast
Published Dec 14, 2022 08:48
Updated Dec 14, 2022 09:12
Oxford Biomedica strikes new AAV agreements with US firms
Sharecast - Oxford Biomedica said on Wednesday that its Oxford Biomedica Solutions unit had inked the deals with the undisclosed firms, with the subsidiary set to provide its full platform to support its new partners' pre-clinical gene therapy programmes.
The London-listed firm did not provide any financial terms related to the deals.
Chairman Dr Roch Doliveux said: "Securing four new AAV customers in 2022 exceeds our original stated target of two new customers by the end of 2022. We are making considerable progress towards becoming a global viral vector leader across all key vector types, with this momentum in Oxford Biomedica Solutions adding to the strength and depth of our UK-based operations.
"AAV is a significant, high-growth market, and the cadence of new business wins further reinforces our confidence in the potential of our AAV platform, which has already demonstrated high-titre product quality and a full breadth of capabilities. We enter 2023 with great confidence and look forward to continuing to build our position as a world-class, innovation-led CDMO delivering life-changing and life-altering therapies to patients ."
As of 0845 GMT, Oxford Biomedica shares were down 0.28% at 381.94p.
Reporting by Iain Gilbert at Sharecast.com
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.